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Background. Diabetes is a risk factor for delayed graft function in kidney transplantation, and hyperglycemia increases ischemia
reperfusion injury in animal models. Methods. To explore the role of perioperative hyperglycemia in ischemia reperfusion injury,
we conducted a prospective study of 40 patients undergoing living donor renal transplantation. Blood glucose levels were
monitored intraoperatively, and serum samples were obtained at the time anesthesia was induced and one hour after allograft
reperfusion. The percentage change in neutrophil gelatinase-associated lipocalin (NGAL), a protein whose expression is increased
with renal ischemia, was then used to determine the extent of injury. Results. In a multivariate model including recipient, donor,
and transplant factors, recipient blood glucose >160mg/dL at the time of allograft reperfusion (β 0.19, P-value < 0.01), warm
ischemia time >30 minutes (β 0.11, P-value 0.13), and recipient age (β 0.05, P-value 0.05) were associated with percentage change
in NGAL. These same predictors were associated with the percentage change in creatinine on postoperative day 2. Conclusions.
Hyperglycemia is associated with increased ischemic injury in renal transplantation. Both creatinine and NGAL, a marker of
ischemic injury and renal function, fall less rapidly in patients with elevated blood glucose.
1.Introduction
The success of renal transplantation continues to be limited
byischemiareperfusioninjury,whichis thedominant mech-
anism in the development of delayed graft function (DGF).
Commonly deﬁned as the need for dialysis within seven days
of transplant, DGF is greatly inﬂuenced by factors that lead
togreaterischemicinjury,suchasprolongedcoldstorageand
procurementfromexpandedcriteriaornonheartbeatingdo-
nors. Beyond the need for short-term dialysis, DGF aﬀects
long-term outcomes and has been associated with a greater
incidence of rejection and decreased graft survival [1–4].
Recently, diabetes has emerged as another risk factor for
DGF [5, 6]. Higher glucose levels in donors have also been
linked to worse prerecovery renal function [7]. In animal
models, hyperglycemia has been shown to increase ischemia
reperfusion injury. For example, hyperglycemic diabetic
mice suﬀer larger myocardial infarcts, and rabbits with
tight glycemic control have less spinal cord injury than
hyperglycemic mice [8–10]. In addition, we have shown that
hyperglycemia at the time of warm ischemia increases renal
injury in nondiabetic Lewis rats [11]. In our experiments,
rats with hyperglycemia at the time ischemia was induced
hadhigherterminalcreatininelevelsandhistologicalfeatures
of more severe acute tubular necrosis compared to normo-
glycemic rats. However, these diﬀerences were not observed
when hyperglycemia was induced two hours after ischemia
was induced. These ﬁndings indicate that hyperglycemia
increasesischemiareperfusioninjury,andthatthiseﬀectmay
be limited to a window around the time of injury.
Although the extent of ischemic injury has been docu-
mented in animal models, demonstrating similar results in
humans can be challenging because of the risk of obtaining
tissue for direct pathologic examination. However, novel
biomarkers have been developed that correlate well with
acute kidney injury due to ischemic insults [12]. Neutrophil
gelatinase-associated lipocalin (NGAL) is emerging as an
excellent marker of acute kidney injury. NGAL is 25-kDa2 Journal of Transplantation
protein that is covalently bound to gelatinase from neu-
trophils. Normally found at low levels in multiple tissues, its
expression is increased in direct response to ischemic injury.
In particular, NGAL is one of the earliest and most strongly
expressed proteins in the kidney after ischemic injury [13–
15]. Increased NGAL expression has been detected as early as
two hours after cardiopulmonary bypass in patients who go
on to develop acute kidney injury [16, 17]. NGAL levels have
also been reliably linked to DGF and the degree of allograft
injury in renal transplantation. NGAL expression in biopsy
specimens from renal allografts taken one hour after re-
perfusion is strongly correlated with peak serum creatinine
and DGF [18]. Similarly, urine NGAL levels on the day of
surgery clearly identiﬁed kidney transplant recipients who
wentontodevelopDGF,withanoverallareaunderthecurve
of 0.9 [19]. More recently, NGAL levels have been found to
start at elevated levels in kidney transplant recipients and
stayed elevated in patients who would develop DGF, thereby,
supporting the use of the change or relative change in NGAL
as a marker for injury [20].
Given the role of recipient diabetes in DGF [5, 6]a n d
mounting evidence that hyperglycemia increases ischemia
reperfusion injury, we undertook this study to determine
if intraoperative hyperglycemia increases ischemic injury in
renal transplantation using serum NGAL as our primary
outcome.
2.SubjectsandMethods
2.1. Study Design and Patients. We prospectively enrolled
a cohort of 40 adult patients undergoing living donor
renal transplantation and their donors at the University of
California,SanFrancisco(UCSF)betweenDecember1,2008
andJune15,2009.ThestudywasapprovedbytheCommittee
on Human Research at UCSF, and informed consent was
obtained. One patient was dropped from the study because
of enrollment in a concurrent experimental drug trial. We
selected living donor transplantation because it is performed
on an elective basis, thereby, allowing us to minimize the
eﬀect of cold ischemia time and donor and intraoperative
factors. All organ procurement was completed via laparo-
scopic donor nephrectomy [21]. The allograft was then put
oniceandtransportedtotherecipientoperationwhereitwas
ﬂushed and prepared for transplantation. After giving each
recipient 500mg of methylprednisolone and either rabbit
antithymocyte antibody (Thymoglobulin, Genzyme Corpo-
ration, Cambridge, Mass, USA) or basiliximab (Simulect,
Novartis, East Hanover, NJ) as induction immunosuppres-
sion, the graft was anastamosed to the external iliac arteries
and veins via an extraperitoneal approach. Intravenous
furosemide and mannitol were infused before graft reper-
fusion. Warm ischemia time was equivalent to anastomotic
time.
Although NGAL levels are an excellent marker of acute
injury and predictor of DGF, they can change quickly and are
variable between individual recipients. Therefore, we used
the percentage change in serum NGAL level as our primary
outcome.Inparticular,wemeasuredabaselineleveljustafter
the induction of anesthesia to minimize external factors and
focusedonthepercentagechangeinNGALinordertonegate
the variability between patients.
2.2. Data Collection. Blood samples were obtained from the
recipients after anesthesia was induced (baseline) and one
hour after the reperfusion of the allograft. Serum samples
werethenaliquotedandstoredat −20◦C. Blood glucose con-
centrations were determined at the point of care at baseline,
the time of reperfusion, and one hour after reperfusion via
glucometer. Data was collected on recipients (age, gender,
bodymassindex(BMI),diabetes,causeofrenalfailure,panel
reactive antibody (PRA), number of previous transplants),
donors (age, gender, BMI), and transplant factors (warm
ischemia time, induction immunosuppression regimen, and
volume of intraoperative intravenous ﬂuids(IVF)).
After transplantation, serum creatinine was measured on
each postoperative day (POD) while the patient was hos-
pitalized. Patients underwent follow-up for 90 days and data
on any episodes of rejection and a follow-up creatinine at 90
days (±7 days) were recorded.
NGAL levels were determined via enzyme-linked im-
mune-absorbance assay (ELISA) kits commercially prepared
by R and D systems (Minneapolis, Minn, USA). The spec-
imens were then grouped into batches of 10 and tested in
duplicate every month such that no specimen was stored for
more than one month. Controls were sampled from healthy
volunteers with no renal disease (n = 5). Color intensity
was read at 450nm with wavelength correction at 570nm
on the Tecan Inﬁnite 200 Plate Reader (Tecan, M¨ annedorf,
Switzerland). The R2 for the standard curve on every plate
exceeded 0.99.
2.3. Statistical Analysis. All categorical values were reported
as simple percentages, and all continuous variables were
reported as means ± standard deviations.
Todeterminethefactorsthataﬀectthepercentagechange
in NGAL at one hour, the aforementioned donor, recipient,
and transplant variables were analyzed using univariate
linear regression. Recipient blood glucose was analyzed as
both a continuous and dichotomous predictor (deﬁned as
blood glucose >160 at the time of reperfusion). Given our
clinical suspicion and evidence of greater injury with blood
glucosesexceeding160mg/dL,ourﬁnalmodelsincorporated
hyperglycemia as a dichotomous predictor. Because we were
interested in ischemic injury, both intra-operative glucose
level and warm ischemic time were included in the ﬁnal
multivariate model. Interaction terms were not explored
based on a lack of clinical suspicion. The ﬁnal multivariate
model was then created by backwards stepwise elimination
with a P-value of 0.2 as the cut-oﬀ. This technique for
predictor selection was also applied to model the percentage
change in serum creatinine on POD 2. Model diagnostics
were checked to ensure that the underlying assumptions of
linearity, normality, and constant variance were not violated.
Correlations between the percentage change in NGAL
and changesin serumcreatinine were tested with Spearman’s
correlationcoeﬃcients.STATA10statisticalsoftwarepackageJournal of Transplantation 3
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Figure 1: Pattern of intra-operative glucose levels for diabetic
(n = 18) and nondiabetic patients (n = 21) during kidney
transplantation. Whiskers span the 5th and 95th percentiles of all
data. Dots represent outliers.
was used for all calculations. All P values were two tailed and
P values ≤ 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Donor and Recipient Characteristics. Data was obtained
for 39 living donors who were all healthy volunteers without
any comorbid conditions. Forty-six percent were men, the
average age was 40.79 ± 11.17 years, and the average BMI
was 26.03±3.56kg/m2. Most donors were Caucasian (54%),
followed by Hispanic (25%), Black (13%), and Asian/Paciﬁc
Islander (8%).
Data was obtained for 39 recipients, 51% of whom
w e r em e n .T h ea v e r a g ea g ew a s4 7 .41 ± 12.78 years, and
the average BMI was 26.30 ± 5.09kg/m2. Recipients were
most commonly Caucasian (54%) followed by Hispanic
(28%), Black (13%), and Asian/Paciﬁc Islander (2%). Forty-
six percent were diabetic. The recipients also had an average
panel reactive antibody of 11% and 15% of them had a prior
kidney transplant. Twenty-six percent of recipients had a
warm ischemic time in excess of 30 minutes and received an
average of 3.30 ± 0.85 liters of IVF intraoperatively. Induc-
tion immunosuppression consisted of either Thymoglobulin
(33%) or Simulect (66%).
Post-operatively, there were no recorded episodes of
hypotension (systolic blood pressure <100 or mean arterial
pressure <60mmHg). None of the recipients required dialy-
sis prior to discharge.
3.2. Glucose Levels during Transplant. Intra-operative glu-
cose levels consistently increased from the beginning to end
of the case for both diabetic and nondiabetic recipients
(Figure 1). Two patients received intra-operative insulin
infusions, and three additional patients received bolus
insulin during their operations. Even when patients who
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Figure 2: (a) Percentage change in NGAL levels at one hour
by clinically deﬁned glucose level (80–120mg/dL, n = 15; 121–
160mg/dL, n = 14; and >160mg/dL, n = 1 0 )a tt h et i m eo f
allograft reperfusion. (b) Percentage change in creatinine on POD
2 by clinically deﬁned glucose level (80–120mg/dL, n = 15; 121–
160mg/dL, n = 14; and >160mg/dL, n = 1 0 )a tt h et i m eo f
allograft reperfusion. Statistical signiﬁcance determined by analysis
of variance. Whiskers span the 5th and 95th percentiles of all data.
Dots represent outliers.
were treated for hyperglycemia were included, diabetic
recipients had higher glucose levels initially (99.29 versus
144.83mg/dL, P = 0.02), at the time of reperfusion
(114.29 versus 155.61mg/dL, P<0.01), and one hour after
reperfusion (119.52 versus 160.83, P<0.01). However,
nondiabetics were still prone to hyperglycemia with 7 (33%)
recipients reaching a serum blood glucose of >120mg/dL at
the time of reperfusion, with a peak value of 198mg/dL in
one non-diabetic patient.
3.3. Predictors of Percentage Change in NGAL. Compared to
controls (42.35 ± 17.31ng/mL, n = 5), recipient NGAL
levels were elevated at baseline (639.77 ± 270.66ng/mL)
and fell, on average, one hour after reperfusion (488.43 ±
210.82ng/mL). However, NGAL levels fell less rapidly and4 Journal of Transplantation
Table 1
(a) Univariate models of percentage change in NGAL.
Characteristic β Coeﬃcient 95% Conﬁdence interval P-value
Recipient age (per 10 years) 0.07 0.02 to 0.11 <0.01
Recipient gender (male) 0.12 −0.01 to 0.25 0.07
Recipient race (compared to white)
Black −0.13 −0.33 to 0.07 0.20
Hispanic −0.14 −0.29 to 0.01 0.07
Asian/Paciﬁc Islander −0.08 −0.38 to 0.22 0.59
Blood glucose (per 10 unit increase) 0.02 0.01 to 0.03 <0.01
Blood glucose > 160mg/dL 0.19 0.04 to 0.33 0.02
Recipient diabetes 0.18 0.07 to 0.30 <0.01
Panel reactive antibody −0.12 −0.38 to 0.14 0.36
Recipient body mass index 0.01 −0.001 to 0.02 0.09
Warm ischemic time (>30min) 0.14 −0.01 to 0.28 0.06
Intra-operative IVF (per liter) 0.03 −0.06 to 0.12 0.49
Thymoglobulin induction (compared to
Simulect) 0.002 −0.15 to 0.15 0.97
Donor age (per 10 years) 0.05 −0.01 to 0.1 0.10
Donor gender (male) −0.02 −0.15 to 0.12 0.79
Donor race (compared to caucasian)
Black −0.12 −0.33 to 0.08 0.24
Hispanic −0.11 −0.27 to 0.05 0.18
Asian/Paciﬁc Islander −0.11 −0.37 to 0.14 0.38
Donor BMI −0.005 −0.02 to 0.01 0.62
(b) Multivariate model of percentage change in NGAL.
Characteristic β Coeﬃcient 95% Conﬁdence interval P-value
Blood glucose > 160mg/dL 0.19 0.06 to 0.33 <0.01
Warm ischemic time (>30min) 0.11 −0.04 to 0.25 0.13
Recipient age (per 10 year increase) 0.05 0 to 0.10 0.05
even increased as recipient blood glucose at reperfusion
increased (Figure 2(a)).
Univariate linear regression revealed that recipient age,
blood glucose at the time of allograft reperfusion (both con-
tinuous and dichotomous predictors) and recipient diabetes
were all statistically signiﬁcant predictors of the percentage
changeinNGAL(Table 1(a)).Warmischemiatime,recipient
gender, recipient BMI recipient race, total IVF, induction
immunosuppression, donor age, donor gender, donor race,
and donor BMI were not signiﬁcant predictors.
When each of the variables from the univariate analysis
was incorporated into a multivariable model and then
eliminated in a stepwise fashion, recipient blood glucose
>160mg/dL emerged as a statistically signiﬁcant predictor of
the percentage change in NGAL (Table 1(b)).
3.4. Creatinine as a Marker of Renal Function. Recipient cre-
atininedecreasedonaveragefromPOD0(6.81±2.78mg/dL)
to POD 2 (2.57±1.64mg/dL). Once again, serum creatinine
fell less rapidly as blood glucose increased (Figure 2(b)).
Similar to our NGAL analysis, we used both univariate
and multivariate linear regression to analyze how blood
glucose at reperfusion aﬀected the percentage change in cre-
atinine, a more traditional marker of renal function. Uni-
variate analysis revealed that blood glucose at reperfusion,
recipient age, recipient diabetes, recipient BMI, donor age,
induction immunosuppression, and warm ischemia time
>30 minutes were all statistically signiﬁcant predictors of the
change in creatinine on POD 2. Recipient gender, recipient
race, PRA, total IVF, donor gender, donor race, and donor
BMI were not statistically signiﬁcant predictors of the per-
centage change in creatinine (Table 2(a)).
The ﬁnal multivariate model was then created. Once
again,bloodglucose>160mg/dLatreperfusion,warmische-
mia time >30 minutes, and recipient age were all statistically
signiﬁcant. Recipient BMI also emerged as a predictor of the
change in creatinine in our ﬁnal model (Table 2(b)).
Similarly, we calculated correlation coeﬃcients to see
how well the percentage change in NGAL correlated with
changes in recipient creatinine. We found that percentage
change in NGAL at one hour showed good correlation with
the percentage change in creatinine on POD 2 (Rho = 0.38,
P = 0.02).Journal of Transplantation 5
Table 2
(a) Percentage change in creatinine on post-operative day two.
Characteristic β Coeﬃcient 95% Conﬁdence interval P-value
Recipient age (per 10 years) 0.05 −0.02 to 0.11 0.15
Recipient gender (male) 0.11 −0.05 to 0.27 0.18
Recipient race (compared to white)
Black 0.02 −0.23 to 0.26 0.88
Hispanic −0.21 −0.29 to 0.02 0.03
Asian/Paciﬁc Islander −0.14 −0.51 to 0.22 0.43
Blood glucose (per 10 unit increase) 0.02 0.001 to 0.03 0.04
Blood glucose > 160mg/dL 0.20 0.02 to 0.39 0.03
Recipient diabetes 0.16 0.001 to 0.32 0.05
Panel reactive antibody −0.26 −0.58 to 0.05 0.10
Recipient body mass index 0.02 0.01 to 0.04 <0.01
Warm ischemic time (>30min) 0.32 0.16 to 0.48 <0.01
Intra-operative IVF (per liter) 0.09 −0.01 to 0.20 0.09
Thymoglobulin induction (compared to
simulect)
−0.20 −0.37 to -0.02 0.03
Donor age (per 10 years) 0.09 0.02 to 0.16 0.02
Donor gender (male) −0.02 −0.15 to 0.11 0.79
Donor race (compared to caucasian)
Black 0.04 −0.21 to 0.30 0.74
Hispanic −0.15 −0.35 to 0.05 0.13
Asian/Paciﬁc Islander −0.08 −0.40 to 0.24 0.61
Donor BMI 0.002 −0.02 to 0.03 0.84
(b) Multivariate model of percentage change in creatinine on post-operative day two.
Characteristic β Coeﬃcient 95% Conﬁdence interval P-value
Blood glucose > 160mg/dL 0.16 0.02 to 0.30 0.03
Warm ischemic time (>30min) 0.23 0.07 to 0.40 <0.01
Recipient age (per 10 years) 0.06 0.002 to 0.1 0.04
Recipient BMI 0.01 −0.001 to 0.03 0.07
3.5. Renal Function at 90 Day Follow-Up Visit. At the 90-
day follow-up visit after transplant, every recipient had
a functioning allograft with a mean glomerular ﬁltra-
tion rate (GFR) of 66.14 ± 18.65mL/min/1.73m2. Of the
38 patients with follow-up data, 17 (45%) had a GFR of
less than 60mL/min/1.73m2. Using logistic regression, we
found that a glucose exceeding 160mg/dL at the time of
allograft reperfusion was associated with a GFR of less
than 60mL/min/1.73m2 (odds ratio 7.78, 95% CI 1.34 to
45.09, P-value 0.02). Due to a limited number of recipients
with GFR less than 60mL/min/1.73m2,w ew e r en o ta b l e
to perform a more complex multivariable analysis. When
analyzed as continuous variables, higher blood glucose at the
timeofreperfusionwasassociatedwithlowerGFRat90days.
However, this relationship was not statistically signiﬁcant
(β =− 0.41, 95%CI −1.68 to 0.87, P-value 0.51) (Figure 3).
Similarly, we set out to determine if recipient GFR at
90 days was related to the percentage change in NGAL at
one hour. Linear regression demonstrated that a more rapid
decline in NGAL at one hour was strongly correlated with
the GFR at 90 days (β =− 0.53, 95% CI −0.86 to −0.020,
P<0.01) (Figure 4).
4. Discussion
Theresultsofourstudyelucidatetheroleofhyperglycemiain
ischemiareperfusioninjuryduringrenaltransplantationand
have clinical implications for the perioperative management
of glucose levels. Furthermore, our ﬁndings provide more
information for the use of serum NGAL as a diagnostic tool.
This study is the ﬁrst to document intra-operative trends
in blood glucose levels during renal transplantation for
both diabetic and non-diabetic recipients. While diabetic
recipients were clearly at greater risk for intra-operative
hyperglycemia, 33% of non-diabetic recipients reached a
blood glucose exceeding 120mg/dL. These patterns imply
more rigorous glucose monitoring, and treatment may be
warranted in all patients undergoing transplant. From a
diagnosticperspective,thisstudyisalsotheﬁrsttodocument
a drop in serum NGAL levels as early as one hour after6 Journal of Transplantation
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Figure 4: Scatter Plot of percentage change in NGAL at one hour
against GFR at 90 days after transplant. Dots represent data points.
Solid line represents linear line of best ﬁt.
transplant. Serum NGAL levels were markedly elevated and
began to fall almost immediately after living donor renal
transplantation. This decrease ﬁts with the near instant
urine output and rapidly falling creatinine clinically seen in
living donor renal transplantation. Furthermore, high initial
levels and rapid changes limit the utility of using any single
NGAL measurement for the purpose of clinical prediction.
Instead, an overall trajectory or relative change should be
consideredwhenusingserumNGALinpatientswithexisting
renal disease. Additionally, the percentage change in serum
NGAL at one hour correlated well with the percentage
change in creatinine 2 days after transplantation as well as
the recipients’ GFR at 90 days. These ﬁndings are consistent
with those in previous studies and reinforce NGAL’s utility
as a marker for injury and short-term graft function in renal
transplantation [18–20].
Of greater clinical importance, elevated glucose level
at the time of reperfusion was inversely proportional to
the percentage change in serum NGAL and creatinine. In
other words, increasing blood glucose led to greater ischemia
reperfusion injury as evidenced by changes in these markers.
Even though NGAL levels fell in most patients, these levels
fells less rapidly and even increased when the allograft was
exposed to higher glucose levels at the time of reperfusion.
Similarly, serum creatinine fells less rapidly with increasing
blood glucose at the time of reperfusion. This phenomenon
may imply that recipients with peri-operative hyperglycemia
are at greater risk for DGF. As recipient blood glucose rises,
the extent of ischemia reperfusion injury, and therefore the
risk of DGF, may also increase. Overall, this pattern of injury
is likely due to greater oxidative stress and inﬂammatory
response, which ﬁts with our animal model in which rats
with hyperglycemia at the time of injury suﬀered higher
terminal creatinine and greater acute tubular necrosis [11].
This relationship between hyperglycemia and ischemia
reperfusion injury may explain, in part, the mechanism by
which recipient diabetes leads to DGF. Although glucose
levels increased both in diabetic and non-diabetic recipients
during transplantation, diabetic recipients had much higher
levels. Diabetes and blood glucose level at the time of
reperfusion were clearly predictors of the percentage change
in NGAL according to our univariate analysis. However,
when we included both in our multivariate model, diabetes
wasnolongerastatisticallysigniﬁcantpredictor.Thisﬁnding
supports the theory that hyperglycemia is the mechanism
by which diabetes leads to DGF in kidney transplant
recipients. Fortunately, this eﬀect can be attenuated with
greater attention to peri-operative glucose levels. Although
targeting glucose levels <100mg/dL can be diﬃcult and
potentially dangerous, our analysis demonstrates a potential
beneﬁt to any reduction in glucose level. Therefore, we
believe that glucose levels should be checked in patients at
risk for hyperglycemia and treated according to standardized
protocols.
Despite the strength of being a prospective study, our
analysis has some limitations. Use of the living donor
population allowed us to eliminate cold ischemia time and
minimize variation in donor characteristics but prevented us
from analyzing clinical outcomes such as DGF. Furthermore,
the size of our population made it diﬃcult to strictly
control for every potential confounding factor, such as exact
blood pressure throughout the case. The use of NGAL as
a surrogate for ischemia reperfusion injury also raises a
number of questions. While numerous studies link NGAL
to graft function in renal transplantation, these studies vary
in the type of NGAL tested (serum versus urine), the time
points collected, and the method of comparison (absolute
versus relative change in levels). We think that our use of
the relative or percentage change in NGAL levels is critical
in serum samples given the fact that patients with end stage
renal disease have markedly elevated and variable levels at
baseline. However, one clear metric for how to use NGAL
and interpret it clinically has yet to be established.
Overall, our study is a starting point to determine if
peri-operative hyperglycemia has a clear eﬀect on clinical
outcomesinrenaltransplantation.Westillneedtodetermine
if the observed eﬀects of elevated glucose can be reversed
withbetterglucosecontrol.Similarly,ifelevatedglucosedoesJournal of Transplantation 7
increase ischemia reperfusion injury, it is not known how
long the allograft is susceptible to injury or how long tight
glucose control would be required to prevent injury. Most
importantly, we need to determine if clinically signiﬁcant
endpoints like DGF and overall graft survival are clearly
aﬀected by intra-operative glucose levels. We have already
begun to study the eﬀect of glycemic control in deceased
organ donors in prospective randomized trials and hope to
extend this work to renal transplant recipients.
5. Brief Summary
Diabetes has emerged as a risk factor for delayed graft
function in renal transplantation. In order to elucidate the
mechanism behind this association, we prospectively studied
the eﬀect of intra-operative glucose levels on neutrophil
gelatinase-associated lipocalin (NGAL), a marker of acute
injury, and creatinine in living donor renal transplant
recipients.BothNGALandcreatininewereadverselyaﬀected
by increasing glucose levels.
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